<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1387">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624503</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIOCOVID</org_study_id>
    <nct_id>NCT04624503</nct_id>
  </id_info>
  <brief_title>Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19</brief_title>
  <acronym>CARDIO-COVID</acronym>
  <official_title>Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19 (Rilevanza Clinica e Prognostica Del Coinvolgimento Cardiovascolare Nei Pazienti Affetti da COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanitas Hospital, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanitas Hospital, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 infection has been associated with numerous cardiac manifestations. Indeed,&#xD;
      SARS-CoV-2 may impact on cardiovascular system through a direct myocardial infection or a&#xD;
      secondary cardiac involvement due to hypoxia or metabolic supply-demand imbalance or&#xD;
      prothrombotic inflammatory state. As a consequence of and besides acute myocardial damages,&#xD;
      COVID-19 could also determine chronic cardiovascular consequences, with a significant impact&#xD;
      on long-term prognosis, quality of life and functional capacity of COVID-19 survivors.&#xD;
&#xD;
      On this basis, we aim to define the clinical and prognostic effects of myocardial involvement&#xD;
      in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 infection has been associated with numerous cardiac manifestations. Indeed,&#xD;
      SARS-CoV-2 may impact on cardiovascular system through a direct myocardial infection or a&#xD;
      secondary cardiac involvement due to hypoxia or metabolic supply-demand imbalance or&#xD;
      prothrombotic inflammatory state. As a consequence of and besides acute myocardial damages,&#xD;
      COVID-19 could also determine chronic cardiovascular consequences, with a significant impact&#xD;
      on long-term prognosis, quality of life and functional capacity of COVID-19 survivors.&#xD;
&#xD;
      On this basis, we aim to define the clinical and prognostic effects of myocardial involvement&#xD;
      in COVID-19 patients, with a 1-month and 6-month follow-up composed of clinical evaluation,&#xD;
      electrocardiogram, trans-thoracic echocardiogram, cardiovascular magnetic resonance, chest&#xD;
      computerized tomography scan and cardiopulmonary exercise test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality due to cardiovascular causes at 1 month after hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Mortality due to cardiovascular causes at 6 months after hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality due to all causes at 1 month after hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Mortality due to all causes at 6 months after hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality)</measure>
    <time_frame>1 month</time_frame>
    <description>Major adverse cardiovascular events at 1 month after hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality)</measure>
    <time_frame>6 months</time_frame>
    <description>Major adverse cardiovascular events at 6 months after hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>6 months</time_frame>
    <description>NYHA functional class: from I (no limitation of physical activity) to IV (severe limitation with symptoms at rest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular systolic function (cardiac magnetic resonance, echocardiography)</measure>
    <time_frame>6 months</time_frame>
    <description>Left ventricular systolic function evaluated with multimodality imaging</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <condition>Myocardial Injury</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Failure</condition>
  <condition>Cardiovascular Morbidity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients for COVID-19.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: patients who were hospitalized for COVID-19&#xD;
&#xD;
        Exclusion Criteria: None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluigi Condorelli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giulio Stefanini, Prof.</last_name>
    <phone>0282247384</phone>
    <email>giulio.stefanini@hunimed.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Stefanini, Prof</last_name>
      <phone>0282247384</phone>
      <email>giulio.stefanini@hunimed.eu</email>
    </contact>
    <investigator>
      <last_name>Gianluigi Condorelli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulio Stefanini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piergiuseppe Agostoni, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Auxologico San Luca</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Badano, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Donato</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Guazzi, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituti Clinici Scientifici Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivlia Priori, Prof.ssa</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Stefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, De Marco A, Briani M, Bocciolone M, Bragato R, Corrada E, Gasparini GL, Marconi M, Monti L, Pagnotta PA, Panico C, Pini D, Regazzoli D, My I, Kallikourdis M, Ciccarelli M, Badalamenti S, Aghemo A, Reimers B, Condorelli G; Humanitas COVID-19 Task Force. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020 Oct;106(19):1512-1518. doi: 10.1136/heartjnl-2020-317322. Epub 2020 Aug 14.</citation>
    <PMID>32817312</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Humanitas Hospital, Italy</investigator_affiliation>
    <investigator_full_name>Giulio Stefanini</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular involvement</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

